But in Kuznik's study, through network meta-analysis, cemiplimab monotherapy was compared with pembrolizumab and chemotherapy regimen, and it was a cost-effective scheme for treating NSCLC patients with PD-L1 expression ≥ 50% across a 30-year time horizon [20]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.